Free Trial
NYSE:ALUR

Allurion Technologies (ALUR) Stock Price, News & Analysis

Allurion Technologies logo
$2.38 +0.02 (+0.81%)
As of 03:02 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Allurion Technologies Stock (NYSE:ALUR)

Key Stats

Today's Range
$2.33
$2.42
50-Day Range
$2.18
$3.66
52-Week Range
$2.15
$88.75
Volume
20,548 shs
Average Volume
714,426 shs
Market Capitalization
$11.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.83
Consensus Rating
Buy

Company Overview

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.

Allurion Technologies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
68th Percentile Overall Score

ALUR MarketRank™: 

Allurion Technologies scored higher than 68% of companies evaluated by MarketBeat, and ranked 667th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Allurion Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Allurion Technologies has only been the subject of 2 research reports in the past 90 days.

  • Read more about Allurion Technologies' stock forecast and price target.
  • Earnings Growth

    Earnings for Allurion Technologies are expected to grow in the coming year, from ($9.96) to ($7.39) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Allurion Technologies is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Allurion Technologies is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Allurion Technologies' valuation and earnings.
  • Percentage of Shares Shorted

    3.43% of the float of Allurion Technologies has been sold short.
  • Short Interest Ratio / Days to Cover

    Allurion Technologies has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Allurion Technologies has recently decreased by 64.08%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Allurion Technologies does not currently pay a dividend.

  • Dividend Growth

    Allurion Technologies does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.43% of the float of Allurion Technologies has been sold short.
  • Short Interest Ratio / Days to Cover

    Allurion Technologies has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Allurion Technologies has recently decreased by 64.08%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Allurion Technologies has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Allurion Technologies this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added Allurion Technologies to their MarketBeat watchlist in the last 30 days. This is a decrease of -90% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Allurion Technologies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $26,800.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    22.40% of the stock of Allurion Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 21.39% of the stock of Allurion Technologies is held by institutions.

  • Read more about Allurion Technologies' insider trading history.
Receive ALUR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allurion Technologies and its competitors with MarketBeat's FREE daily newsletter.

ALUR Stock News Headlines

You need this much to retire comfortably
Top analysts are reporting that the average person will need at least $2 million to retire comfortably these days… But when it takes an average of 41 years to turn a $100K of retirement savings into $1 million… The odds are not in our favor… We can’t promise results or guarantee against losses, but there’s no need to go another day without finding out how to target extra income with Jack’s help.
Allurion Technologies reports Q4 EPS ($7.95), consensus ($5.70)
See More Headlines

ALUR Stock Analysis - Frequently Asked Questions

Allurion Technologies' stock was trading at $10.75 at the beginning of 2025. Since then, ALUR shares have decreased by 78.1% and is now trading at $2.35.
View the best growth stocks for 2025 here
.

Allurion Technologies Inc. (NYSE:ALUR) issued its quarterly earnings results on Wednesday, March, 26th. The company reported ($7.00) EPS for the quarter, missing analysts' consensus estimates of ($5.00) by $2.00. The firm earned $5.59 million during the quarter, compared to analysts' expectations of $5.60 million.
Read the conference call transcript
.

Allurion Technologies's stock reverse split before market open on Friday, January 3rd 2025. The 1-25 reverse split was announced on Tuesday, December 24th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 2nd 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of ALUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Allurion Technologies investors own include NVIDIA (NVDA), Meta Platforms (META), Nuvation Bio (NUVB), Taiwan Semiconductor Manufacturing (TSM), Advanced Micro Devices (AMD), Amprius Technologies (AMPX) and Applied Digital (APLD).

Company Calendar

Last Earnings
3/26/2025
Today
4/29/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NYSE:ALUR
Previous Symbol
NYSE:ALUR
Fax
N/A
Employees
501
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$22.83
High Stock Price Target
$50.00
Low Stock Price Target
$2.50
Potential Upside/Downside
+859.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-80,610,000.00
Pretax Margin
-70.14%

Debt

Sales & Book Value

Annual Sales
$32.11 million
Price / Cash Flow
N/A
Book Value
($36.95) per share
Price / Book
-0.06

Miscellaneous

Free Float
2,011,000
Market Cap
$11.41 million
Optionable
Optionable
Beta
-0.61

This page (NYSE:ALUR) was last updated on 4/29/2025 by MarketBeat.com Staff
From Our Partners